Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 1:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 574 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Disease Clear all
Completed Phase 3 Interventional

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

NCT00659048
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 2 Interventional

A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy

NCT00080210
View directory record Official record
Conditions
Gout
Interventions
Puricase
Drug
Lead sponsor
Savient Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 2 Interventional Results available

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

NCT01578278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis

NCT00244543
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 13, 2026, 1:58 PM EDT
Completed No phase listed Observational

Systemic Reactions to Allergen Immunotherapy Amd Skin Testing

NCT00594802
View directory record Official record
Conditions
SYSTEMIC REACTION
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Sep 13, 2026, 1:58 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Allergy and Immunology Natural History Study

NCT05584488
View directory record Official record
Conditions
Immune Deficiency, Immune Dysregulation Disorder, Allergic Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 1 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients

NCT00932256
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
STAHIST NDC #58407-536-01
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 13, 2026, 1:58 PM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 13, 2026, 1:58 PM EDT
Enrolling by invitation Not applicable Interventional

Rate of Allergic Contact Dermatitis and Cosmetic Outcomes

NCT06957444
View directory record Official record
Conditions
Allergic Contact Dermatitis, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
Sylke Adhesive Dressing, Exofin Skin Glue, Suture Strip Plus
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

NCT01689363
View directory record Official record
Conditions
Allergic Skin Reaction
Interventions
Hyaluronidase, Histamine, Saline
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

NCT00794144
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Olopatadine Hydrochloride Nasal Spray Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years to 5 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2010 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

NCT04418999
View directory record Official record
Conditions
Keratoconus, Dry Eye, Allergy
Interventions
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly
Drug
Lead sponsor
Illinois College of Optometry
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose

NCT00882115
View directory record Official record
Conditions
Allergic Airway Disease
Interventions
Broccoli sprout extract (BSE)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 13, 2026, 1:58 PM EDT
Not listed Phase 4 Interventional

Ocular Allergy Treatment Practical Impact Trial

NCT01808768
View directory record Official record
Conditions
Allergic Conjunctivitis, Rhinoconjunctivitis
Interventions
Alcaftadine
Drug
Lead sponsor
Starx Research Center, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Edison, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 1Phase 2 Interventional

FluMist in Egg Allergic Patients

NCT01248208
View directory record Official record
Conditions
Egg Allergy, Eligible for Vaccination Against Influenza
Interventions
FluMist intranasal influenza vaccine, Intramuscular influenza injection ("flu shot")
Biological
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
6 Months and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 13, 2026, 1:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cutaneous and Systemic Reactions to Metal Implants

NCT02483728
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
Patch Test
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Mineola, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasal Ocular Reflexes Contribute to Eye Symptoms

NCT00117832
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Azelastine nasal spray
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 4 Interventional Results available

Assessment of Alcon's Ocular Image Quantification System

NCT01282138
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT01024608
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 13, 2026, 1:58 PM EDT
Terminated Phase 2 Interventional Results available

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

NCT02075008
View directory record Official record
Conditions
Asthma
Interventions
QGE031
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 76 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Evansville, Indiana • Owensboro, Kentucky • Waldorf, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 13, 2026, 1:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeated Insult Patch Test

NCT03474874
View directory record Official record
Conditions
Dermatitis, Allergy, Contact Allergy
Interventions
NeoMatriX Collagen Dressing
Device
Lead sponsor
NeXtGen Biologics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 13, 2026, 1:58 PM EDT
Withdrawn Phase 2 Interventional

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

NCT00604578
View directory record Official record
Conditions
Asthma, Airway Inflammation, Airflow Obstruction, Airway Hyperactivity
Interventions
Pioglitazone Hydrochloride
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 13, 2026, 1:58 PM EDT